Clinical Trials Browser

Phase 1 × Rituximab × Tumor-Agnostic × Clear all

NCT03783403 2024-09-19

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Phase 1 Terminated

Neoplasms